Overview

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

Status:
Terminated
Trial end date:
2018-09-25
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine if SOM230 is safe and effective for the treament of cluster headache.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Pasireotide
Sumatriptan